carbapenems has been researched along with amikacin in 85 studies
| Studies (carbapenems) | Trials (carbapenems) | Recent Studies (post-2010) (carbapenems) | Studies (amikacin) | Trials (amikacin) | Recent Studies (post-2010) (amikacin) |
|---|---|---|---|---|---|
| 7,355 | 147 | 5,277 | 4,739 | 485 | 1,316 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (2.35) | 18.7374 |
| 1990's | 7 (8.24) | 18.2507 |
| 2000's | 10 (11.76) | 29.6817 |
| 2010's | 42 (49.41) | 24.3611 |
| 2020's | 24 (28.24) | 2.80 |
| Authors | Studies |
|---|---|
| Jacobus, NV; Petersen, PJ; Testa, RT; Weiss, WJ | 1 |
| Livermore, DM; Said, AA | 1 |
| Inderlied, CB; Lancero, MG; Young, LS | 1 |
| Beuscart, C; Mouton, YJ | 1 |
| Sjursen, H; Solberg, CO | 1 |
| Schuler, D | 1 |
| Giamarellos-Bourboulis, EJ; Giamarellou, H; Grecka, P | 1 |
| Eltahawy, AT | 1 |
| Babini, GS; Bates, J; Livermore, DM; Palepou, MF; Woodford, N | 1 |
| Bantar, C; Di Chiara, M; Nicola, F; Relloso, S; Smayevsky, J | 1 |
| Chinzei, T; Ishida, A; Tasaka, K | 1 |
| Adukauskiene, D; Dudzevicius, V; Ryskus, L; Sakalauskas, R; Vitkauskiene, A | 1 |
| Cheng, KC; Chuang, YC; Huang, GC; Wu, LT; Yu, WL | 1 |
| Doi, M; Fujiue, Y; Kuwabara, M; Muroki, K; Shimizu, S; Watanabe, Y; Yano, S | 1 |
| Alp, E; Aygen, B; Metan, G; Sumerkan, B | 1 |
| Chang, CY; Chang, YL; Hsu, CK; Hsueh, PR; Kuo, LC; Lai, CC; Liao, CH | 1 |
| Adams, JM; Doi, Y; Paterson, DL; Yamane, K | 1 |
| Gilbert, D | 1 |
| Aytac, S; Cengiz, AB; Cetin, M; Ceyhan, M; Secmeer, G; Tuncer, M; Yetgin, S; Yildirim, I | 1 |
| Amicosante, G; Falcone, M; Mancini, C; Mezzatesta, ML; Perilli, M; Stefani, S; Venditti, M | 1 |
| Akduman, D; Ankarali, H; Aydemir, H; Celebi, G; Engin, H; Gokmen, A; Keskin, AS; Oztoprak, N; Piskin, N | 1 |
| Ersoy, Y; Görgeç, S; Kuzucu, C; Yetkin, F | 1 |
| Chong, Y; Hong, HL; Jeong, SH; Kang, JO; Kim, JS; Kim, MN; Lee, K; Park, YJ; Shin, JH; Yong, D | 1 |
| Anan, N; Ito, A; Nakamura, R; Toba, S; Tsuji, M | 1 |
| Bernusset, S; Cattoen, C; Cuzon, G; Naas, T; Nordmann, P | 1 |
| Cheng, A; Hsueh, PR; Huang, YT; Lee, YC; Liao, CH; Liu, CY; Tsai, HY | 1 |
| Dimopoulou, D; Galanakis, E; Kofteridis, DP; Maraki, S; Ntaoukakis, M; Samonis, G; Sarchianaki, E; Spathopoulou, T | 1 |
| Chen, YH; Chen, YS; Chuang, YC; Ho, CM; Hsueh, PR; Huang, CC; Ko, WC; Lee, YL; Liu, CE; Liu, YC; Liu, YM; Lu, PL; Ni, Y; Tang, HJ; Toh, HS; Wang, JH; Xu, Y; Yu, KW | 1 |
| Dowzicky, MJ; Fernández-Canigia, L | 1 |
| Aypak, C; Bayram, I; Bayram, Y; Parlak, M | 1 |
| Douthwaite, S; Gonzalez-Zorn, B; Gutierrez, B; Hidalgo, L; Hopkins, KL; Ovejero, CM; Prasad, KN; Shukla, S; Woodford, N | 1 |
| Alba, L; Clock, SA; Kubin, CJ; Saiman, L; Tabibi, S; Whittier, S | 1 |
| Bordi, E; Capone, A; D'Arezzo, S; Di Caro, A; Mazzarelli, A; Petrosillo, N; Principe, L | 1 |
| Apter, S; Eviatar, T; Grossman, E; Hoffman, C; Keller, N; Rosman, Y; Thaler, M | 1 |
| Hagiwara, K; Hirama, T; Kanazawa, M; Kawana, H; Kawashima, A; Masumoto, A; Mio, T; Nagata, M; Shiono, A | 1 |
| Hall, RM; Holt, KE; Nigro, SJ; Pickard, D | 1 |
| Ahmed, SS; Alp, E; Demiraslan, H; Dinc, G; Doganay, M; Elmali, F | 1 |
| Bhattacharya, S; Bhaumik, J; Chandy, M; Goel, G; Mukherjee, S | 1 |
| Batbaatar, G; Bolormaa, E; Huang, AH; Huang, YT; Kao, CY; Khosbayar, T; Udval, U; Urangoo, Z; Wu, HM; Wu, JJ; Yan, JJ | 1 |
| Barišić, Z; Goic-Barisic, I; Hrenović, J; Kaliterna, M; Kaliterna, V; Tonkić, M | 1 |
| Caro-Vega, JM; García-Quintanilla, M; McConnell, MJ; Moreno-Martínez, P; Pachón, J; Pulido, MR | 1 |
| Dinic, M; Kocic, B; Mitic, R; Mladenovic-Antic, S; Petrovic, J; Randjelovic, G; Velickovic-Radovanovic, R | 1 |
| Badal, RE; Biedenbach, DJ; Giao, PT; Hung Van, P; Phuong, DM; Su Minh Tuyet, N; Thi Thanh Nga, T; Vu Trung, N | 1 |
| Ansari, S; Chaudhary, N; Dhital, R; Gautam, R; Khatiwada, S; Puri, R; Shrestha, S; Thapa, S | 1 |
| Hackel, MA; Hoban, DJ; Karlowsky, JA; Lob, SH; Sahm, DF | 1 |
| Alonso-Isa, M; Benítez-Sala, R; García-Rojo, E; Gil-Moradillo, J; González-Padilla, DA; Justo-Quintas, J; Lara-Isla, A; Medina-Polo, J; Passas-Martínez, JB; Sopeña-Sutil, R; Tejido-Sánchez, Á | 1 |
| Alp, E; Badal, R; Gulay, Z; Koksal, I; Korten, V; Lob, S; Mete, B; Mulazimoglu, L; Oguz, VA; Tabak, F; Unal, S; Yilmaz, G; Zarakolu, P | 1 |
| Alp, E; Çetin, M; Elmali, F; Kaynar, L; Kürkçüoglu, CA; Metan, G; Yozgat, N | 1 |
| Li, B; Li, L; Peters, BM; Shirtliff, ME; Xie, J; Xu, Z; Yu, G | 1 |
| Akhi, MT; Ghotaslou, R; Kafil, HS; Khalili, Y; Naghili, B; Sheikhalizadeh, V; Yousefi, S | 1 |
| Cho, B; Chung, NG; Han, SB; Jeong, DC; Kang, JH; Kim, HS; Kim, SK; Lee, DG; Lee, JW; Park, BK | 1 |
| Li, Y; Liu, J; Liu, XJ; Lyu, Y; Xue, F | 1 |
| Bush, K; Kashikar, A; Zhang, Y | 1 |
| Béchet, S; Biscardi, S; Bonacorsi, S; Cixous, E; Cohen, R; Craiu, I; Dubos, F; Galerne, A; Grimprel, E; Hees, L; Hentgen, V; Jung, C; Levy, C; Lorrot, M; Madhi, F; Timsit, S | 1 |
| Chatsuwan, T; Singkham-In, U | 1 |
| Cai, Y; Wang, J; Wang, R; Yang, D | 1 |
| Barth, AL; Martins, AF; Nunes, LS; Wilhelm, CM | 1 |
| Ahmad, N; Ahuja, SD; Akkerman, OW; Alffenaar, JC; Anderson, LF; Baghaei, P; Bang, D; Barry, PM; Bastos, ML; Behera, D; Benedetti, A; Bisson, GP; Boeree, MJ; Bonnet, M; Brode, SK; Brust, JCM; Cai, Y; Caumes, E; Cegielski, JP; Centis, R; Chan, ED; Chan, PC; Chang, KC; Charles, M; Cirule, A; D'Ambrosio, L; Dalcolmo, MP; de Vries, G; Dheda, K; Esmail, A; Flood, J; Fox, GJ; Fréchet-Jachym, M; Fregona, G; Gayoso, R; Gegia, M; Gler, MT; Gu, S; Guglielmetti, L; Holtz, TH; Hughes, J; Isaakidis, P; Jarlsberg, L; Kempker, RR; Keshavjee, S; Khan, FA; Kipiani, M; Koenig, SP; Koh, WJ; Kritski, A; Kuksa, L; Kvasnovsky, CL; Kwak, N; Lan, Z; Lange, C; Laniado-Laborín, R; Lee, M; Leimane, V; Leung, CC; Leung, EC; Li, PZ; Lowenthal, P; Maciel, EL; Marks, SM; Mase, S; Mbuagbaw, L; Menzies, D; Migliori, GB; Milanov, V; Miller, AC; Mitnick, CD; Modongo, C; Mohr, E; Monedero, I; Nahid, P; Ndjeka, N; O'Donnell, MR; Padayatchi, N; Palmero, D; Pape, JW; Podewils, LJ; Reynolds, I; Riekstina, V; Robert, J; Rodriguez, M; Schnippel, K; Seaworth, B; Seung, KJ; Shim, TS; Singla, R; Smith, SE; Sotgiu, G; Sukhbaatar, G; Tabarsi, P; Tiberi, S; Trajman, A; Trieu, L; Udwadia, ZF; van der Werf, TS; Veziris, N; Viiklepp, P; Vilbrun, SC; Walsh, K; Westenhouse, J; Yew, WW; Yim, JJ; Zetola, NM; Zignol, M | 1 |
| Gao, Y; Guo, R; Lu, L; Shen, H; Yu, Y; Zhu, C | 1 |
| Cho, SY; Chung, DR; Kang, CI; Kim, SH; Ko, JH; Lee, NY; Peck, KR; Song, JH | 1 |
| Demir, M; Kazanasmaz, H | 1 |
| Çağ, Y; Can, F; Ergonul, O; Hacıseyitoğlu, D; Işık, ME; Menekşe, Ş; Şahin, S | 1 |
| Essack, SY; Feldman, C; Maningi, NE; Mbelle, N; Modipane, L; Osei Sekyere, J | 1 |
| Bhandari, S; Hishinuma, T; Kirikae, T; Morioka, S; Shahi, RK; Sherchan, JB; Sherchand, JB; Shrestha, S; Tada, T; Twi, RT; Uchida, H | 1 |
| Burgess, DS; Clark, JA; Kulengowski, B | 1 |
| Ali, HB; Asuman, B; Kubra, HU; Sarah, AF; Sreylis, N; Yeliz, TC | 1 |
| Bragantini, D; Carrara, E; Cattaneo, P; Chiamenti, M; Ellis, S; Franceschi, F; Giske, CG; Lodise, T; Menchinelli, G; Piddock, LJV; Righi, E; Sanguinetti, M; Savoldi, A; Scudeller, L; Tacconelli, E | 1 |
| Baldissera, GS; Mathos, D; Rigatto, MH; Rodrigues, D; Sartori, A; Zavascki, AP | 1 |
| Bai, J; Ding, M; Li, Q; Liang, Q; Liang, S; Wang, G; Yan, X; Zhang, B; Zhang, F; Zhou, Y | 1 |
| Feng, H; He, L; Wu, H; Xu, P; Zhang, H | 1 |
| Kwan, S; Magallon, J; Oakley-Havens, CL; Phan, K; Ramirez, MS; Reeves, C; Tolmasky, ME; Vu, P | 1 |
| Gunawan, C; Hamidian, M; Harmer, CJ; Mann, R; Rafei, R | 1 |
| Li, J; Liu, Y; Wang, H; Wu, G; Xu, X | 1 |
| Ashley, EA; Becker, K; Gysin, M; Haldimann, K; Hinfonthong, P; Hobbie, SN; Hon, PY; Hopkins, J; Kaewphanderm, N; Kesteman, T; Ling, CL; Nguyen, TH; Pham, TD; Roberts, T; Sengduangphachanh, A; Simmalavong, M; Simpson, AJH; Tan, P; Tran, HH; Turner, P; van Doorn, HR; Vasoo, S | 1 |
| Jia, P; Jia, X; Kang, M; Li, R; Li, X; Liu, X; Xu, Y; Yang, Q; Yu, W; Zhu, Y | 1 |
| Bennett, JW; Corey, BW; Doi, Y; Iovleva, A; Kwak, YI; Lebreton, F; Luo, TL; McElheny, CL; McGann, PT; Preston, LN; Snesrud, E | 1 |
| Bai, Y; Fan, X; Fu, L; Tian, C; Wang, S; Xing, M; Zhao, Y | 1 |
| Choi, YJ; Jeong, SH; Junglim, K; Kim, HS; Kim, YA; Kim, YR; Ryoo, NH; Shin, JH; Shin, KS; Uh, Y | 1 |
| A Katouah, H; Acker, M; Al Hadi, R; Ali, M; Alserihi, R; Alyami, J; Alzahrani, E; Amirazodi, M; Amrillah, T; Andreassen, OA; Ardiccioni, C; Ask, H; Atzori, C; Ayorech, Z; Azambuja, JH; Azmi, R; Badem, S; Balci, AB; Bali, H; Baranova, NS; Barantsevich, ER; Barocci, S; Bauer, RJ; Bauermeister, JA; Bazhenova, TA; Biagetti, G; Bigdeli, F; Bonar, EE; Bouloumis, T; Bu, Y; Cai, Z; Cakiroglu, B; Canetto, SS; Cao, J; Caucci, S; Cerbo, I; Chen, C; Chen, J; Chen, Q; Chen, Y; Cheng, B; Cheng, X; Chinappi, M; Choya, A; Cicconardi, F; Cipolletta, S; Colasurdo, G; Costabile, BK; Coughlin, LN; Crippa, P; D'Agostino, M; D'Annessa, I; Daryanoosh, F; Das, R; Davey Smith, G; Davidson, BR; Davies, NM; Davis, TME; Davis, WA; de Rivas, B; Demir, D; Deng, Z; Dhanya, TM; Di Marino, D; Divya, KM; Dong, N; Drinkwater, JJ; Ekholuenetale, M; El-Bindary, AA; El-Bindary, MA; El-Desouky, MG; Elsayed, H; Ema, K; Endraswari, PD; Entilli, L; Ettl, T; Eyado, A; Fan, X; Fang, W; Farina, M; Florimbio, AR; Fowobaje, KR; Gaeini, A; Gao, XM; Gao, Y; Ghaemi, R; Ghelardi, E; Gilmutdinov, IF; Gochicoa-Rangel, L; Goncu, MT; Gözüküçük, R; Grammatikopoulos, P; Gu, Y; Guan, ZJ; Gucu, A; Guldberg, R; Gungor, O; Guo, W; Gutiérrez-Ortiz, JI; Guzmán-Boulloud, N; Guzmán-Valderrábano, C; Głuszko, A; Hama, A; Hamada, M; Han, J; Hashimoto, T; Havdahl, A; Hayashita, T; He, X; Helgeland, Ø; Hinck, AP; Hinck, CS; Holtzapple, M; Hou, Y; Howe, LD; Hu, B; Hu, H; Huang, L; Huang, Z; Hughes, AM; Hussain, G; Ibidoja, OJ; Ichikawa, D; Imber, C; Islam, MR; Iype, S; Jaber, J; Jacobs, R; Jafry, AT; Ji, L; Ji, X; Jiang, L; Jiang, Y; Jie, HFM; Jie, HM; Johansen, MP; Johansson, S; Juan, LX; Juan, W; Kahraman, N; Kallinger, I; Kang, H; Karakulova, YV; Kärmer, T; Kataoka, S; Kato, K; Kawashima, N; Kazim, AH; Khalil, MR; Kitazawa, H; Klimesova, YM; Kojima, S; Kose, M; Kostakis, ID; Koushkie Jahromi, M; Krishna, GA; Krizova, D; La Teana, A; Lan, K; Li, J; Li, JZ; Li, M; Li, R; Li, S; Li, Y; Li, Z; Liu, H; Liu, J; Liu, KG; Liu, L; Liu, Q; Liu, T; Liu, X; Lomachenko, KA; López-Fonseca, R; Ludwig, N; Luo, A; Luo, L; Luo, Y; Lupetti, A; M El-Metwaly, N; Ma, K; Maemura, R; Magnus, P; Manakin, YV; Mancia, F; Mashood, LO; Matsumoto, K; Mehrabi, A; Meier, JK; Mekonnen, Y; Mencarelli, D; Menzo, S; Mikagi, A; Mironov, VS; Misawa-Suzuki, T; Miwata, S; Mizuta, Y; Mohanan, PV; Mondal, J; Morici, P; Morita, K; Morozzo Della Rocca, B; Morris, T; Morsali, A; Morzhukhina, MV; Motta, S; Muramatsu, H; Naidu, R; Narita, A; Narita, K; Nasralla, D; Nemcokova, M; Netukova, M; Nishikawa, E; Nishio, N; Niu, X; Niu, Y; Njølstad, P; Notarstefano, V; Nugroho, MA; Nørgård, BM; Okuno, Y; Olokede, O; Ong, SP; Osailan, A; Ouyang, Z; Ozyazicioglu, AF; Pan, F; Parui, A; Paul, R; Pavoni, E; Payne, TE; Peng, X; Pérez-Padilla, R; Perta, N; Peter, SC; Pierantoni, L; Pietrowska, M; Pissanou, T; Pollok, JM; Prasetio, A; Putra, FS; Qiang, C; Qiao, L; Qutob, HMH; Raptis, DA; Razzo, BM; Reichborn-Kjennerud, T; Reichert, TE; Remigio-Luna, A; Rexha, J; Rivani, E; Rizzato, C; Romagnoli, A; Rossolini, GM; Sa, LY; Saad, RA; Sakaguchi, H; Salesi, M; Salsabilla, Z; Sanderson, E; Sanderson, P; Savitha, DP; Schulz, D; Seker, IB; Selvaganapathy, PR; Sha, D; Shah, SF; Shaikhomar, OA; Sharma, D; Shi, C; Shi, P; Shrotri, A; Sidiq, DH; Simonov, SV; Singh, AK; Song, C; Song, T; Spanier, G; Spoerl, S; Staropoli, A; Statsenko, ME; Steinhauer, S; Stosic, A; Studeny, P; Sugaya, T; Sun, S; Sun, X; Sunbul, SA; Supandi, AR; Suzuki, K; Suzuki, Y; Szczepański, MJ; Takahashi, Y; Taniguchi, R; Tao, Y; Tesli, M; Thirión-Romero, I; Tong, D; Trucchi, E; Tsuchido, Y; Turchetti, C; Turkina, SV; Turner, AW; Uldbjerg, N; Vinale, F; Wakamatsu, M; Walton, MA; Wang, C; Wang, Q; Wang, W; Wang, Y; Wang, Z; Wehberg, S; Wei, ZL; Wen, B; Whiteside, TL; Whittingham, MS; Widodo, ADW; Widłak, P; Wright, AI; Wu, H; Wu, Y; Wu, YL; Xiang, LG; Xiao, G; Xie, B; Xie, L; Xin, H; Xiong, J; Xiong, X; Xu, C; Xu, S; Yagubskii, EB; Yakushev, IA; Yang, H; Yang, J; Yao, J; Yao, ZX; Ye, J; Yerneni, SS; Yirgu, A; Yoshida, N; Yoshida, T; Young, SD; Yu, DN; Yuksel, A; Zac, J; Zac, S; Zarifkar, AH; Zhai, Y; Zhang, F; Zhang, H; Zhang, JW; Zhang, L; Zhang, Q; Zhang, X; Zhang, Y; Zhao, D; Zhao, J; Zhao, M; Zheng, D; Zheng, J; Zhou, G; Zhou, H; Zhu, P; Zhu, T; Zhu, Y; Zimmerman, MA; Zou, X | 1 |
| Cao, M; Wang, T; Wei, Q; Zhu, W; Zhu, Y | 1 |
| Huang, Y; Liu, H; Lu, W; Peng, J; Qin, G; Wu, D; Xiao, J | 1 |
| Acman, M; Chiu, CH; Hamawandi, A; Lindsay, JA; Readman, JB; Sharland, M; Standing, JF | 1 |
| Abdellatif, GR; Aboshanab, KM; Mabrouk, SS; Zaid, ASA | 1 |
| Fandiño, C; Juliet, C; Ramos, MP; Ramos-Castaneda, JA; Rioseco, ML; Torres-Castillo, LC | 1 |
| Aiesh, BM; Maali, Y; Omarya, S; Qandeel, F; Sabateen, A; Sholi, S; Taha, AA; Taha, SA; Zyoud, SH | 1 |
3 review(s) available for carbapenems and amikacin
| Article | Year |
|---|---|
Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis.
Topics: Amikacin; Antitubercular Agents; Capreomycin; Carbapenems; Clofazimine; Diarylquinolines; Drug Therapy, Combination; Fluoroquinolones; Humans; Kanamycin; Levofloxacin; Linezolid; Moxifloxacin; Recurrence; Treatment Failure; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary | 2018 |
Systematic review and meta-analysis of in vitro efficacy of antibiotic combination therapy against carbapenem-resistant Gram-negative bacilli.
Topics: Amikacin; Anti-Bacterial Agents; Azabicyclo Compounds; Carbapenems; Ceftazidime; Cephalosporins; Colistin; Drug Combinations; Drug Resistance, Bacterial; Drug Synergism; Drug Therapy, Combination; Fosfomycin; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Imipenem; In Vitro Techniques; Microbial Sensitivity Tests; Polymyxins; Rifampin; Tazobactam; Tobramycin | 2021 |
Impact of dexamethasone and tocilizumab on hematological parameters in COVID-19 patients with chronic disease.
Topics: Acetaminophen; Acetylcarnitine; Acetylcholinesterase; Acids; Acinetobacter baumannii; Acinetobacter Infections; Adaptation, Psychological; Adolescent; Adsorption; Adult; Aged; Alcohol Drinking; Alzheimer Disease; Amikacin; Ammonia; Anaerobiosis; Animals; Anorexia; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Anxiety; Aptamers, Nucleotide; Asthenia; Attention Deficit Disorder with Hyperactivity; Bacterial Proteins; Beryllium; beta-Lactamases; Biofuels; Biomass; Biosensing Techniques; Bismuth; Blister; Body Mass Index; Body Surface Area; Boronic Acids; Brain; Breast Neoplasms; Butyrylcholinesterase; Cannabis; Carbapenems; Carbonyl Cyanide m-Chlorophenyl Hydrazone; Carboxylic Acids; Carcinoma, Hepatocellular; Cardiovascular Diseases; Carnitine; Case-Control Studies; Catalysis; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Child; China; Cholinesterase Inhibitors; Clarithromycin; Clostridioides; Clostridioides difficile; Clostridium Infections; Cohort Studies; Colistin; Colitis; Colon; Coloring Agents; Coronary Artery Bypass; Creatinine; Crystalloid Solutions; Cytokines; Depression; Dextran Sulfate; Dextrans; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Diarrhea; Dietary Supplements; Diphenhydramine; Disease Models, Animal; Disease Outbreaks; Double-Blind Method; Doxorubicin; Drosophila; Drug Tapering; Dysbiosis; Electrons; Escherichia coli; Extracellular Vesicles; Fatigue; Female; Fermentation; gamma-Cyclodextrins; Gastrointestinal Microbiome; Glucose; Graft Survival; Graft vs Host Disease; Head and Neck Neoplasms; Heart Arrest, Induced; Hematopoietic Stem Cell Transplantation; High-Intensity Interval Training; Hippocampus; Humans; Hydrogen-Ion Concentration; Hypertension; Incidence; Interferon-gamma; Italy; Kinetics; Klebsiella Infections; Klebsiella pneumoniae; Lab-On-A-Chip Devices; Lactoferrin; Larva; Length of Stay; Lignin; Liver; Liver Neoplasms; Liver Transplantation; Living Donors; Low Back Pain; Lung; Lung Volume Measurements; Macrophages; Male; Melphalan; Men; Mendelian Randomization Analysis; Meropenem; Methane; Mice; Mice, Inbred C57BL; Microbial Sensitivity Tests; Mitochondrial Proteins; Molecular Docking Simulation; Molecular Structure; Mothers; Motivation; Mycoplasma; Mycoplasma hominis; Mycoplasma Infections; NAD; Nanocomposites; Nanoparticles; Nanotubes, Carbon; Naproxen; Neovascularization, Pathologic; Neurons; Nitrates; Nucleolin; Opuntia; Paratyphoid Fever; Phenotype; Phosphatidylinositol 3-Kinases; Phytochemicals; Plant Extracts; Pregnancy; Prevalence; Prospective Studies; Proto-Oncogene Proteins c-akt; Pulmonary Disease, Chronic Obstructive; Rats; Rats, Wistar; Resveratrol; Retrospective Studies; Rifampin; Risk Factors; RNA, Messenger; Selenium; Sleep; Social Behavior; Soil; Soil Pollutants; Squamous Cell Carcinoma of Head and Neck; Staphylococcus aureus; Structure-Activity Relationship; Suicidal Ideation; Suicide; Superoxide Dismutase-1; Surveys and Questionnaires; Swimming; Syndrome; Tannins; Temperature; Transforming Growth Factor beta; Transplantation Conditioning; Treatment Outcome; Triple Negative Breast Neoplasms; Troponin T; Tumor Microenvironment; United Kingdom; Ureaplasma; Ureaplasma urealyticum; Urinary Tract Infections; Viscum; Waste Disposal Facilities; Wastewater; Water; Water Pollutants, Chemical; Wolfiporia; Young Adult | 2022 |
7 trial(s) available for carbapenems and amikacin
| Article | Year |
|---|---|
Empirical monotherapy with meropenem in serious bacterial infections. Meropenem Study Group.
Topics: Adolescent; Adult; Aged; Amikacin; Bacterial Infections; Carbapenems; Ceftazidime; Community-Acquired Infections; Cross Infection; Drug Therapy, Combination; Drug Tolerance; Hospitalization; Humans; Meropenem; Middle Aged; Respiratory Tract Infections; Sepsis; Thienamycins; Time Factors; Treatment Outcome; Urinary Tract Infections | 1995 |
Safety and efficacy of meropenem in patients with septicaemia: a randomised comparison with ceftazidime, alone or combined with amikacin.
Topics: Adult; Aged; Amikacin; Carbapenems; Ceftazidime; Drug Therapy, Combination; Drug Tolerance; Hospitalization; Humans; Meropenem; Middle Aged; Sepsis; Thienamycins; Treatment Outcome | 1995 |
Safety and efficacy of meropenem in hospitalised children: randomised comparison with cefotaxime, alone and combined with metronidazole or amikacin. Meropenem Paediatric Study Group.
Topics: Amikacin; Anti-Bacterial Agents; Bacterial Infections; Carbapenems; Cefotaxime; Cephalosporins; Child; Child, Preschool; Drug Therapy, Combination; Drug Tolerance; Humans; Infant; Meropenem; Metronidazole; Thienamycins | 1995 |
"The truth, if it exists, is in the details".
Topics: Amikacin; Anti-Bacterial Agents; Carbapenems; Doripenem; Humans; Imipenem; Pneumonia, Ventilator-Associated; Severity of Illness Index; Treatment Outcome | 2008 |
Piperacillin/tazobactam plus amikacin versus carbapenem monotherapy as empirical treatment of febrile neutropenia in childhood hematological malignancies.
Topics: Adolescent; Amikacin; Anti-Bacterial Agents; Bacteria; Bacterial Infections; Carbapenems; Child; Child, Preschool; Drug Therapy, Combination; Enzyme Inhibitors; Female; Humans; Leukemia, Myeloid, Acute; Male; Neutropenia; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2008 |
Piperacillin-tazobactam versus carbapenem therapy with and without amikacin as empirical treatment of febrile neutropenia in cancer patients: results of an open randomized trial at a university hospital.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amikacin; Anti-Bacterial Agents; Antineoplastic Agents; Bacterial Infections; Carbapenems; Drug Eruptions; Drug Therapy, Combination; Female; Fever; Humans; Male; Middle Aged; Multivariate Analysis; Neoplasms; Neutropenia; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prospective Studies; Survival Rate; Young Adult | 2010 |
Impact of dexamethasone and tocilizumab on hematological parameters in COVID-19 patients with chronic disease.
Topics: Acetaminophen; Acetylcarnitine; Acetylcholinesterase; Acids; Acinetobacter baumannii; Acinetobacter Infections; Adaptation, Psychological; Adolescent; Adsorption; Adult; Aged; Alcohol Drinking; Alzheimer Disease; Amikacin; Ammonia; Anaerobiosis; Animals; Anorexia; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Anxiety; Aptamers, Nucleotide; Asthenia; Attention Deficit Disorder with Hyperactivity; Bacterial Proteins; Beryllium; beta-Lactamases; Biofuels; Biomass; Biosensing Techniques; Bismuth; Blister; Body Mass Index; Body Surface Area; Boronic Acids; Brain; Breast Neoplasms; Butyrylcholinesterase; Cannabis; Carbapenems; Carbonyl Cyanide m-Chlorophenyl Hydrazone; Carboxylic Acids; Carcinoma, Hepatocellular; Cardiovascular Diseases; Carnitine; Case-Control Studies; Catalysis; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Child; China; Cholinesterase Inhibitors; Clarithromycin; Clostridioides; Clostridioides difficile; Clostridium Infections; Cohort Studies; Colistin; Colitis; Colon; Coloring Agents; Coronary Artery Bypass; Creatinine; Crystalloid Solutions; Cytokines; Depression; Dextran Sulfate; Dextrans; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Diarrhea; Dietary Supplements; Diphenhydramine; Disease Models, Animal; Disease Outbreaks; Double-Blind Method; Doxorubicin; Drosophila; Drug Tapering; Dysbiosis; Electrons; Escherichia coli; Extracellular Vesicles; Fatigue; Female; Fermentation; gamma-Cyclodextrins; Gastrointestinal Microbiome; Glucose; Graft Survival; Graft vs Host Disease; Head and Neck Neoplasms; Heart Arrest, Induced; Hematopoietic Stem Cell Transplantation; High-Intensity Interval Training; Hippocampus; Humans; Hydrogen-Ion Concentration; Hypertension; Incidence; Interferon-gamma; Italy; Kinetics; Klebsiella Infections; Klebsiella pneumoniae; Lab-On-A-Chip Devices; Lactoferrin; Larva; Length of Stay; Lignin; Liver; Liver Neoplasms; Liver Transplantation; Living Donors; Low Back Pain; Lung; Lung Volume Measurements; Macrophages; Male; Melphalan; Men; Mendelian Randomization Analysis; Meropenem; Methane; Mice; Mice, Inbred C57BL; Microbial Sensitivity Tests; Mitochondrial Proteins; Molecular Docking Simulation; Molecular Structure; Mothers; Motivation; Mycoplasma; Mycoplasma hominis; Mycoplasma Infections; NAD; Nanocomposites; Nanoparticles; Nanotubes, Carbon; Naproxen; Neovascularization, Pathologic; Neurons; Nitrates; Nucleolin; Opuntia; Paratyphoid Fever; Phenotype; Phosphatidylinositol 3-Kinases; Phytochemicals; Plant Extracts; Pregnancy; Prevalence; Prospective Studies; Proto-Oncogene Proteins c-akt; Pulmonary Disease, Chronic Obstructive; Rats; Rats, Wistar; Resveratrol; Retrospective Studies; Rifampin; Risk Factors; RNA, Messenger; Selenium; Sleep; Social Behavior; Soil; Soil Pollutants; Squamous Cell Carcinoma of Head and Neck; Staphylococcus aureus; Structure-Activity Relationship; Suicidal Ideation; Suicide; Superoxide Dismutase-1; Surveys and Questionnaires; Swimming; Syndrome; Tannins; Temperature; Transforming Growth Factor beta; Transplantation Conditioning; Treatment Outcome; Triple Negative Breast Neoplasms; Troponin T; Tumor Microenvironment; United Kingdom; Ureaplasma; Ureaplasma urealyticum; Urinary Tract Infections; Viscum; Waste Disposal Facilities; Wastewater; Water; Water Pollutants, Chemical; Wolfiporia; Young Adult | 2022 |
76 other study(ies) available for carbapenems and amikacin
| Article | Year |
|---|---|
In vitro and in vivo activities of LJC10,627, a new carbapenem with stability to dehydropeptidase I.
Topics: Amikacin; Animals; Bacterial Infections; Bacteroides fragilis; Carbapenems; Ceftazidime; Cilastatin; Ciprofloxacin; Dipeptidases; Drug Therapy, Combination; Escherichia coli; Female; Imipenem; Klebsiella pneumoniae; Metronidazole; Mice; Microbial Sensitivity Tests; Piperacillin; Pseudomonas aeruginosa; Staphylococcus; Streptococcus; Thienamycins | 1991 |
In-vitro interactions of FCE 22101 with aminoglycosides against gram-negative rods.
Topics: Amikacin; Anti-Bacterial Agents; Carbapenems; Drug Interactions; Gentamicins; Gram-Negative Bacteria; Lactams; Microbial Sensitivity Tests; Tobramycin | 1989 |
Bacteriostatic and bactericidal in-vitro activity of meropenem against clinical isolates, including Mycobacterium avium complex.
Topics: Amikacin; Bacteria; Bacterial Infections; Carbapenems; Drug Synergism; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Meropenem; Microbial Sensitivity Tests; Mycobacterium avium Complex; Thienamycins | 1989 |
In-vitro interactions of DX-8739, a new carbapenem, meropenem and imipenem with amikacin against multiresistant Pseudomonas aeruginosa.
Topics: Amikacin; Anti-Bacterial Agents; Carbapenems; Drug Interactions; Drug Resistance, Multiple; Imipenem; Meropenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Thienamycins | 1996 |
Gram-negative bacilli isolated from patients in intensive care unit: prevalence and antibiotic susceptibility.
Topics: Amikacin; Anti-Bacterial Agents; Anti-Infective Agents; Blood; Carbapenems; Cephalosporins; Ciprofloxacin; Cross Infection; Drug Resistance, Microbial; Gram-Negative Bacteria; Humans; Imipenem; Intensive Care Units; Microbial Sensitivity Tests; Respiratory Tract Infections; Saudi Arabia; Urinary Tract Infections; Wounds and Injuries | 1997 |
Carbapenemase-producing Pseudomonas aeruginosa in UK.
Topics: Amikacin; Anti-Bacterial Agents; Anti-Infective Agents; Bacterial Proteins; beta-Lactam Resistance; beta-Lactamase Inhibitors; beta-Lactamases; Carbapenems; Ceftazidime; Ciprofloxacin; Drug Resistance, Microbial; Enzyme Inhibitors; Gentamicins; Humans; Imipenem; Meropenem; Metalloproteins; Penicillanic Acid; Penicillins; Piperacillin; Pseudomonas aeruginosa; Tazobactam; Thienamycins; United Kingdom | 1998 |
Comparative in vitro bactericidal activity between cefepime and ceftazidime, alone and associated with amikacin, against carbapenem-resistant Pseudomonas aeruginosa strains.
Topics: Amikacin; Anti-Bacterial Agents; Carbapenems; Cefepime; Ceftazidime; Cephalosporins; Drug Resistance, Microbial; Microbial Sensitivity Tests; Pseudomonas aeruginosa | 2000 |
[Antimicrobial activity of carbapenems and the combined effect with aminoglycoside against recent clinical isolates of Pseudomonas aeruginosa].
Topics: Amikacin; Anti-Bacterial Agents; Carbapenems; Drug Synergism; Drug Therapy, Combination; Imipenem; Meropenem; Pseudomonas aeruginosa; Thienamycins | 2002 |
[The rate of isolation of Klebsiella pneumoniae producing extended-spectrum beta-lactamases and resistance to antibiotics].
Topics: Amikacin; Anti-Bacterial Agents; beta-Lactamases; Bronchi; Carbapenems; Cephalosporins; Ciprofloxacin; Gentamicins; Humans; Klebsiella pneumoniae; Microbial Sensitivity Tests; Piperacillin | 2006 |
Clinical experiences of the infections caused by extended-spectrum beta-lactamase-producing Serratia marcescens at a medical center in Taiwan.
Topics: Amikacin; beta-Lactamase Inhibitors; beta-Lactamases; Carbapenems; Cefepime; Cephalosporins; Electrophoresis, Gel, Pulsed-Field; Humans; Imipenem; Microbial Sensitivity Tests; Molecular Epidemiology; Molecular Sequence Data; Polymerase Chain Reaction; Serratia Infections; Serratia marcescens; Taiwan | 2006 |
[Antimicrobial susceptibility of Pseudomonas aeruginosa isolated from urine at one hospital to mainly carbapenem and fluoroquinolone drugs].
Topics: Amikacin; Anti-Infective Agents; Carbapenems; Ceftazidime; Ciprofloxacin; Drug Resistance, Microbial; Fluoroquinolones; Humans; Imipenem; Meropenem; Oxazines; Piperacillin; Pseudomonas aeruginosa; Thienamycins; Urine | 2006 |
Carbapenem-resistant Acinetobacter baumannii: an emerging threat for patients with post-neurosurgical meningitis.
Topics: Acinetobacter baumannii; Adolescent; Adult; Aged; Amikacin; Anti-Bacterial Agents; Carbapenems; Cefepime; Cefoperazone; Cephalosporins; Ciprofloxacin; Drug Resistance, Bacterial; Female; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Imipenem; Male; Meningitis, Bacterial; Meropenem; Microbial Sensitivity Tests; Middle Aged; Neurosurgical Procedures; Postoperative Complications; Thienamycins; Turkey | 2007 |
Multidrug-resistant Acinetobacter baumannii bacteraemia: clinical features, antimicrobial therapy and outcome.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Amikacin; Ampicillin; Anti-Bacterial Agents; Bacteremia; Carbapenems; Drug Resistance, Multiple, Bacterial; Female; Fluoroquinolones; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Retrospective Studies; Sulbactam; Treatment Outcome | 2007 |
Identification of 16S rRNA methylase-producing Acinetobacter baumannii clinical strains in North America.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Amikacin; Aminoglycosides; Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamases; Carbapenems; Electrophoresis, Gel, Pulsed-Field; Humans; Methyltransferases; Microbial Sensitivity Tests; Molecular Sequence Data; North America; RNA, Ribosomal, 16S; Sequence Analysis, DNA | 2007 |
Prolonged bacteraemia caused by VIM-1 metallo-beta-lactamase-producing Proteus mirabilis: first report from Italy.
Topics: Aged; Amikacin; Anti-Bacterial Agents; Bacteremia; beta-Lactamases; Carbapenems; Cefepime; Cephalosporins; Chromosomes, Bacterial; DNA, Bacterial; Humans; Integrons; Italy; Male; Meropenem; Plasmids; Proteus Infections; Proteus mirabilis; Surgical Wound Infection; Thienamycins; Treatment Failure; Treatment Outcome | 2010 |
[Investigation of the susceptibilities of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella spp. strains to ertapenem and other carbapenems].
Topics: Amikacin; Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamases; beta-Lactams; Carbapenems; Ertapenem; Escherichia coli; Escherichia coli Infections; Humans; Imipenem; Klebsiella Infections; Klebsiella oxytoca; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests; Thienamycins | 2011 |
Further increases in carbapenem-, amikacin-, and fluoroquinolone-resistant isolates of Acinetobacter spp. and P. aeruginosa in Korea: KONSAR study 2009.
Topics: Acinetobacter; Acinetobacter Infections; Amikacin; Anti-Bacterial Agents; Carbapenems; Cross Infection; Drug Resistance, Bacterial; Fluoroquinolones; Humans; Pseudomonas aeruginosa; Pseudomonas Infections; Republic of Korea | 2011 |
[In vitro combination effects of doripenem with aminoglycoside or ciprofloxacin against Pseudomonas aeruginosa].
Topics: Amikacin; Aminoglycosides; Anti-Bacterial Agents; Anti-Infective Agents; Carbapenems; Ciprofloxacin; Doripenem; Drug Combinations; Drug Resistance, Bacterial; Drug Synergism; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Tobramycin | 2011 |
First identification of blaIMI-1 in an Enterobacter cloacae clinical isolate from France.
Topics: Adult; Amikacin; Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamases; Carbapenems; Enterobacter cloacae; Enterobacteriaceae Infections; France; Humans; Male; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Pneumonia, Ventilator-Associated; RNA, Ribosomal, 16S; Sequence Analysis, DNA; Tazobactam | 2012 |
Bacteremia caused by Acinetobacter junii at a medical center in Taiwan, 2000-2010.
Topics: Acinetobacter; Acinetobacter Infections; Adult; Aged; Amikacin; Anti-Bacterial Agents; Bacteremia; Carbapenems; Catheter-Related Infections; Central Venous Catheters; Colony Count, Microbial; Cross Infection; Drug Resistance, Bacterial; Female; Hospital Mortality; Humans; Incidence; Male; Microbial Sensitivity Tests; Middle Aged; Minocycline; RNA, Ribosomal, 16S; Sequence Analysis, RNA; Taiwan; Tertiary Care Centers; Tigecycline | 2012 |
Effects of carbapenems and their combination with amikacin on murine gut colonisation by Candida albicans.
Topics: Amikacin; Animals; Anti-Bacterial Agents; Candida albicans; Candidiasis; Carbapenems; Disease Models, Animal; Drug Therapy, Combination; Gastrointestinal Tract; Humans; Male; Mice | 2013 |
Epidemiology and antimicrobial susceptibility profiles of Gram-negative bacteria causing urinary tract infections in the Asia-Pacific region: 2009-2010 results from the Study for Monitoring Antimicrobial Resistance Trends (SMART).
Topics: Amikacin; Anti-Bacterial Agents; Asia; Australasia; beta-Lactamases; beta-Lactams; Carbapenems; Ceftazidime; Drug Resistance, Bacterial; Ertapenem; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prevalence; Prospective Studies; Urinary Tract Infections | 2012 |
Susceptibility of important Gram-negative pathogens to tigecycline and other antibiotics in Latin America between 2004 and 2010.
Topics: Acinetobacter baumannii; Amikacin; Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Drug Resistance, Multiple, Bacterial; Enterobacter; Escherichia coli; Imipenem; Klebsiella oxytoca; Klebsiella pneumoniae; Latin America; Meropenem; Microbial Sensitivity Tests; Minocycline; Serratia marcescens; Thienamycins; Tigecycline; United States; United States Food and Drug Administration | 2012 |
Three-year review of bacteriological profile and antibiogram of burn wound isolates in Van, Turkey.
Topics: Adult; Amikacin; Burns; Carbapenems; Child; Child, Preschool; Drug Resistance, Multiple, Bacterial; Female; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Infections; Male; Retrospective Studies; Turkey | 2013 |
Association of the novel aminoglycoside resistance determinant RmtF with NDM carbapenemase in Enterobacteriaceae isolated in India and the UK.
Topics: Amikacin; Aminoglycosides; Bacterial Proteins; beta-Lactamases; Carbapenems; DNA, Bacterial; Drug Resistance, Multiple, Bacterial; Enterobacteriaceae; Enterobacteriaceae Infections; Gentamicins; Humans; India; Methyltransferases; Molecular Sequence Data; Plasmids; Sequence Analysis, DNA; United Kingdom | 2013 |
In vitro activity of doripenem alone and in multi-agent combinations against extensively drug-resistant Acinetobacter baumannii and Klebsiella pneumoniae.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Amikacin; Anti-Bacterial Agents; Carbapenems; Cross Infection; Doripenem; Drug Resistance, Multiple, Bacterial; Drug Synergism; Humans; Klebsiella Infections; Klebsiella pneumoniae; Microbial Sensitivity Tests; Polymyxin B; Rifampin | 2013 |
In vitro activity of doripenem in combination with various antimicrobials against multidrug-resistant Acinetobacter baumannii: possible options for the treatment of complicated infection.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Amikacin; Anti-Bacterial Agents; Carbapenems; Colistin; Doripenem; Drug Resistance, Multiple, Bacterial; Drug Synergism; Drug Therapy, Combination; Humans; Intensive Care Units; Microbial Sensitivity Tests; Minocycline; Tertiary Healthcare; Tigecycline | 2013 |
Nocardiosis: a 15-year experience in a tertiary medical center in Israel.
Topics: Adrenal Cortex Hormones; Adult; Aged; Amikacin; Carbapenems; Ceftriaxone; Cohort Studies; Encephalitis; Female; Humans; Immunocompromised Host; Israel; Male; Middle Aged; Nocardia Infections; Pleuropneumonia; Retrospective Studies; Risk Factors; Skin Diseases, Bacterial; Soft Tissue Infections; Tertiary Care Centers; Treatment Outcome; Trimethoprim, Sulfamethoxazole Drug Combination | 2013 |
[Case report; a case of lung and skin nocardiosis in a non-immunocompromised patient].
Topics: Aged; Amikacin; Anti-Bacterial Agents; Carbapenems; Diagnosis, Differential; Doripenem; Drainage; Humans; Male; Nocardia asteroides; Nocardia Infections; Opportunistic Infections; Radiography, Thoracic; Skin Diseases, Bacterial; Sputum; Suppuration; Tomography, X-Ray Computed | 2013 |
Carbapenem and amikacin resistance on a large conjugative Acinetobacter baumannii plasmid.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Amikacin; Anti-Bacterial Agents; Australia; Carbapenems; Conjugation, Genetic; DNA Transposable Elements; DNA, Bacterial; Drug Resistance, Bacterial; Gene Order; Gene Transfer, Horizontal; Genes, Bacterial; Humans; Molecular Sequence Data; Plasmids; Sequence Analysis, DNA | 2015 |
Antimicrobial efficacy of doripenem and its combinations with sulbactam, amikacin, colistin, tigecycline in experimental sepsis of carbapenem-resistant Acinetobacter baumannii.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Amikacin; Animals; Anti-Bacterial Agents; Carbapenems; Colistin; Doripenem; Drug Resistance, Multiple, Bacterial; Humans; Male; Mice; Mice, Inbred BALB C; Minocycline; Sepsis; Sulbactam; Tigecycline | 2015 |
Epidemiology of antimicrobial resistance in an oncology center in eastern India.
Topics: Acinetobacter; Amikacin; Anti-Bacterial Agents; Antifungal Agents; Bacterial Infections; Cancer Care Facilities; Carbapenems; Ceftazidime; Ciprofloxacin; Clindamycin; Disk Diffusion Antimicrobial Tests; Drug Resistance, Bacterial; Enterobacteriaceae; Feces; Fluconazole; Gentamicins; Humans; India; Methicillin-Resistant Staphylococcus aureus; Mycoses; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas; Yeasts | 2015 |
Molecular characterization of extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella spp. isolates in Mongolia.
Topics: Amikacin; Anti-Bacterial Agents; Bacterial Typing Techniques; beta-Lactamases; Carbapenems; Electrophoresis, Gel, Pulsed-Field; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Fluoroquinolones; Humans; Klebsiella Infections; Klebsiella pneumoniae; Microbial Sensitivity Tests; Mongolia; Plasmids; Polymerase Chain Reaction | 2016 |
Acinetobacter baumannii in Southern Croatia: clonal lineages, biofilm formation, and resistance patterns.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Amikacin; Ampicillin; Anti-Bacterial Agents; Biofilms; Carbapenems; Croatia; Cross Infection; Drug Resistance, Multiple, Bacterial; Electrophoresis, Gel, Pulsed-Field; Genotype; Humans; Intensive Care Units; Microbial Sensitivity Tests; Monte Carlo Method; Respiratory System; Respiratory Tract Infections; Sulbactam; Urine; Wounds and Injuries | 2015 |
Inhibition of LpxC Increases Antibiotic Susceptibility in Acinetobacter baumannii.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Amidohydrolases; Amikacin; Anti-Bacterial Agents; Azithromycin; Bacterial Proteins; Carbapenems; Drug Resistance, Multiple, Bacterial; Imipenem; Microbial Sensitivity Tests; Minocycline; Rifampin; Tigecycline; Vancomycin | 2016 |
Correlation between antimicrobial consumption and antimicrobial resistance of Pseudomonas aeruginosa in a hospital setting: a 10-year study.
Topics: Amikacin; Anti-Bacterial Agents; Anti-Infective Agents; beta-Lactams; Carbapenems; Drug Resistance, Bacterial; Drug Utilization; Gentamicins; Hospitals; Humans; Imipenem; Meropenem; Pseudomonas aeruginosa; Serbia; Thienamycins | 2016 |
Antimicrobial-resistant Pseudomonas aeruginosa and Acinetobacter baumannii From Patients With Hospital-acquired or Ventilator-associated Pneumonia in Vietnam.
Topics: Acinetobacter baumannii; Amikacin; Anti-Bacterial Agents; beta-Lactamase Inhibitors; beta-Lactams; Carbapenems; Cefepime; Cephalosporins; Cross Infection; Doripenem; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Gentamicins; Humans; Longitudinal Studies; Microbial Sensitivity Tests; Minocycline; Pneumonia, Bacterial; Pneumonia, Ventilator-Associated; Pseudomonas aeruginosa; Tigecycline; Vietnam | 2016 |
Growing Menace of Antibacterial Resistance in Clinical Isolates of Pseudomonas aeruginosa in Nepal: An Insight of Beta-Lactamase Production.
Topics: Amikacin; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenems; China; Cross-Sectional Studies; Drug Resistance, Bacterial; Female; Humans; Male; Microbial Sensitivity Tests; Nepal; Phenotype; Polymyxins; Pseudomonas aeruginosa; Pseudomonas Infections | 2016 |
Antimicrobial susceptibility of Gram-negative ESKAPE pathogens isolated from hospitalized patients with intra-abdominal and urinary tract infections in Asia-Pacific countries: SMART 2013-2015.
Topics: Acinetobacter baumannii; Amikacin; Anti-Infective Agents; Asia; beta-Lactamases; beta-Lactams; Carbapenems; Cephalosporins; Drug Resistance, Multiple, Bacterial; Enterobacter; Ertapenem; Gram-Negative Bacteria; Hospitalization; Humans; Imipenem; Intraabdominal Infections; Klebsiella pneumoniae; Levofloxacin; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Urinary Tract Infections | 2017 |
Prospective study analyzing risk factors and characteristics of healthcare-associated infections in a Urology ward.
Topics: Aged; Aged, 80 and over; Amikacin; Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Catheters, Indwelling; Cross Infection; Cystectomy; Drug Resistance, Microbial; Enterococcus; Escherichia coli; Escherichia coli Infections; Female; Fluoroquinolones; Hospital Units; Humans; Immunosuppression Therapy; Incidence; Klebsiella; Klebsiella Infections; Male; Middle Aged; Prospective Studies; Pseudomonas aeruginosa; Pseudomonas Infections; Risk Factors; Surgical Wound Infection; Urinary Catheters; Urinary Tract Infections; Urology; Vancomycin | 2017 |
Epidemiology and susceptibility of pathogens from SMART 2011-12 Turkey: evaluation of hospital-acquired versus community-acquired urinary tract infections and ICU- versus non-ICU-associated intra-abdominal infections.
Topics: Amikacin; Anti-Bacterial Agents; beta-Lactams; Carbapenems; Cefoxitin; Community-Acquired Infections; Cross Infection; Enterobacteriaceae; Ertapenem; Escherichia coli; Humans; Imipenem; Intensive Care Units; Intraabdominal Infections; Klebsiella pneumoniae; Microbial Sensitivity Tests; Turkey; Urinary Tract Infections | 2017 |
A change for the antibacterial treatment policy to decrease carbapenem consumption at a haematopoietic stem cell transplantation centre.
Topics: Amikacin; Anti-Bacterial Agents; Carbapenems; Cross Infection; Febrile Neutropenia; Guidelines as Topic; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Penicillanic Acid; Piperacillin; Retrospective Studies; Tazobactam; Teicoplanin; Tertiary Care Centers; Treatment Outcome; Turkey; Vancomycin | 2017 |
Clinical features and antimicrobial resistance profiles of important Enterobacteriaceae pathogens in Guangzhou representative of Southern China, 2001-2015.
Topics: Amikacin; Anti-Bacterial Agents; Blood; Carbapenems; Ceftazidime; Cephalosporins; China; Disk Diffusion Antimicrobial Tests; Drug Resistance, Bacterial; Enterobacter; Enterobacteriaceae; Escherichia coli; Humans; Klebsiella pneumoniae; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Sputum; Urinary Tract | 2017 |
Evaluation of Carbapenem Resistance Mechanisms and Its Association with Pseudomonas aeruginosa Infections in the Northwest of Iran.
Topics: Adult; Aged; Aged, 80 and over; Amikacin; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactam Resistance; beta-Lactamases; Carbapenems; Clone Cells; Female; Gene Expression Regulation, Bacterial; Hospitalization; Humans; Iran; Isoenzymes; Male; Microbial Sensitivity Tests; Middle Aged; Molecular Epidemiology; Porins; Pseudomonas aeruginosa; Pseudomonas Infections; Risk Factors; Urinary Tract Infections | 2018 |
Clinical characteristics and outcomes of Pseudomonas aeruginosa bacteremia in febrile neutropenic children and adolescents with the impact of antibiotic resistance: a retrospective study.
Topics: Adolescent; Amikacin; Aminoglycosides; Anti-Bacterial Agents; Bacteremia; Carbapenems; Cephalosporins; Child; Child, Preschool; Drug Resistance, Multiple, Bacterial; Female; Fever; Fluoroquinolones; Humans; Male; Meropenem; Neutropenia; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Thienamycins | 2017 |
Trends in Antimicrobial Resistance against Enterobacteriaceae Strains Isolated from Blood: A 10-year Epidemiological Study in Mainland China (2004-2014).
Topics: Amikacin; Anti-Bacterial Agents; Carbapenems; China; Drug Resistance, Bacterial; Enterobacteriaceae; Escherichia coli; Humans; Imipenem; Microbial Sensitivity Tests; Minocycline; Tigecycline | 2017 |
In vitro activity of plazomicin against β-lactamase-producing carbapenem-resistant Enterobacteriaceae (CRE).
Topics: Amikacin; Aminoglycosides; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenem-Resistant Enterobacteriaceae; Carbapenems; Enterobacteriaceae Infections; Humans; Imipenem; Indiana; Klebsiella pneumoniae; Methyltransferases; Microbial Sensitivity Tests; Sisomicin | 2017 |
Febrile urinary-tract infection due to extended-spectrum beta-lactamase-producing Enterobacteriaceae in children: A French prospective multicenter study.
Topics: Adolescent; Amikacin; Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Child; Child, Preschool; Enterobacteriaceae; Enterobacteriaceae Infections; Female; Fever; France; Humans; Infant; Infant, Newborn; Male; Microbial Sensitivity Tests; Prospective Studies; Risk Factors; Urinary Tract Infections | 2018 |
In vitro activities of carbapenems in combination with amikacin, colistin, or fosfomycin against carbapenem-resistant Acinetobacter baumannii clinical isolates.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Amikacin; Anti-Bacterial Agents; beta-Lactam Resistance; Carbapenems; Colistin; Fosfomycin; Humans; Microbial Sensitivity Tests; Thailand | 2018 |
Amikacin and cefoperazone/sulbactam alone or in combination against carbapenem-resistant Pseudomonas aeruginosa.
Topics: Amikacin; Animals; Anti-Bacterial Agents; beta-Lactam Resistance; Carbapenems; Cefoperazone; Disease Models, Animal; Drug Therapy, Combination; Female; Humans; Luminescent Measurements; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Sulbactam | 2018 |
In vitro antimicrobial activity of imipenem plus amikacin or polymyxin B against carbapenem-resistant Pseudomonas aeruginosa isolates.
Topics: Amikacin; Anti-Infective Agents; Carbapenems; Drug Resistance, Bacterial; Drug Synergism; Humans; Imipenem; Microbial Sensitivity Tests; Polymyxin B; Pseudomonas aeruginosa; Pseudomonas Infections | 2018 |
Infections Caused by Extended-Spectrum
Topics: Amikacin; Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Case-Control Studies; Escherichia coli; Escherichia coli Infections; Female; Humans; Lupus Erythematosus, Systemic; Male; Microbial Sensitivity Tests; Middle Aged; Prevalence; Retrospective Studies; Risk Factors | 2018 |
Evaluation of a Carbapenem-Saving Strategy Using Empirical Combination Regimen of Piperacillin-Tazobactam and Amikacin in Hemato-Oncology Patients.
Topics: Amikacin; Anti-Bacterial Agents; Carbapenems; Drug Resistance, Bacterial; Enterobacteriaceae; Febrile Neutropenia; Humans; Piperacillin, Tazobactam Drug Combination | 2019 |
Uropathogens and antibiotic resistance in the community and hospital-induced urinary tract infected children.
Topics: Adolescent; Amikacin; Ampicillin; Anti-Bacterial Agents; Carbapenems; Child; Child, Preschool; Drug Resistance, Bacterial; Escherichia coli; Female; Humans; Infant; Infant, Newborn; Inpatients; Klebsiella; Male; Microbial Sensitivity Tests; Outpatients; Proteus; Retrospective Studies; Trimethoprim, Sulfamethoxazole Drug Combination; Turkey; Urinary Tract Infections | 2020 |
The effect of colistin resistance and other predictors on fatality among patients with bloodstream infections due to Klebsiella pneumoniae in an OXA-48 dominant region.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amikacin; Anti-Bacterial Agents; Bacteremia; beta-Lactamases; Carbapenems; Colistin; Drug Resistance, Bacterial; Female; Humans; Klebsiella Infections; Klebsiella pneumoniae; Male; Microbial Sensitivity Tests; Middle Aged; Retrospective Studies; Risk Factors; Tertiary Care Centers; Tigecycline; Young Adult | 2019 |
Genomic analysis of two drug-resistant clinical Morganella morganii strains isolated from UTI patients in Pretoria, South Africa.
Topics: Aged, 80 and over; Amikacin; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenems; Drug Resistance, Multiple, Bacterial; Enterobacteriaceae Infections; Female; Genome, Bacterial; Genomics; Humans; Integrons; Male; Microbial Sensitivity Tests; Middle Aged; Morganella morganii; Phylogeny; Plasmids; South Africa; Urinary Tract Infections | 2020 |
Emergence of clinical isolates of highly carbapenem-resistant Klebsiella pneumoniae co-harboring bla
Topics: Amikacin; Aminoglycosides; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenem-Resistant Enterobacteriaceae; Carbapenems; Genome, Bacterial; Humans; Klebsiella Infections; Klebsiella pneumoniae; Microbial Sensitivity Tests; Nepal; Plasmids; Whole Genome Sequencing | 2020 |
In vitro activity of plazomicin compared to other clinically relevant aminoglycosides in carbapenem-resistant Enterobacteriaceae.
Topics: Amikacin; Aminoglycosides; Anti-Bacterial Agents; Carbapenem-Resistant Enterobacteriaceae; Carbapenems; Drug Resistance, Multiple, Bacterial; Gentamicins; Humans; Klebsiella pneumoniae; Microbial Sensitivity Tests; Sisomicin; Tobramycin | 2020 |
Investigation of isepamicin in vitro efficiency in Gram negative bacteria efficacy of isepamicin.
Topics: Amikacin; Aminoglycosides; Anti-Bacterial Agents; Carbapenems; Gentamicins; Gram-Negative Bacteria; Microbial Sensitivity Tests; Netilmicin; Pseudomonas aeruginosa; Tobramycin | 2021 |
Amikacin for the treatment of carbapenem-resistant Klebsiella pneumoniae infections: clinical efficacy and toxicity.
Topics: Acute Kidney Injury; Adult; Aged; Aged, 80 and over; Amikacin; Anti-Bacterial Agents; Carbapenem-Resistant Enterobacteriaceae; Carbapenems; Colistin; Female; Humans; Klebsiella Infections; Klebsiella pneumoniae; Male; Microbial Sensitivity Tests; Middle Aged; Retrospective Studies; Treatment Outcome; Young Adult | 2021 |
Carbapenem-resistant K. pneumoniae exhibiting clinically undetected amikacin and meropenem heteroresistance leads to treatment failure in a murine model of infection.
Topics: Amikacin; Animals; Anti-Bacterial Agents; Carbapenems; Disease Models, Animal; Klebsiella pneumoniae; Meropenem; Mice; Microbial Sensitivity Tests; Treatment Failure | 2021 |
In Vitro Activities of Tigecycline in Combination with Amikacin or Colistin Against Carbapenem-Resistant Acinetobacter baumannii.
Topics: Acinetobacter baumannii; Amikacin; beta-Lactam Resistance; Carbapenems; Colistin; Drug Resistance, Multiple, Bacterial; Drug Synergism; Tigecycline | 2021 |
Amikacin in combination with zinc pyrithione prevents growth of a multidrug-resistant carbapenem-resistant Klebsiella pneumoniae isolate.
Topics: Amikacin; Anti-Bacterial Agents; Carbapenem-Resistant Enterobacteriaceae; Carbapenems; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Humans; Klebsiella Infections; Klebsiella pneumoniae; Microbial Sensitivity Tests; Organometallic Compounds; Pyridines | 2021 |
Variants of Tn
Topics: Acinetobacter baumannii; Acinetobacter Infections; Amikacin; Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Drug Resistance, Bacterial; Genome, Bacterial; Macrolides; Meropenem; Phylogeny; Sequence Alignment | 2022 |
Intravenous plus intraventricular tigecycline-amikacin therapy for the treatment of carbapenem-resistant Klebsiella pneumoniae ventriculitis: A case report.
Topics: Amikacin; Anti-Bacterial Agents; Carbapenem-Resistant Enterobacteriaceae; Carbapenems; Central Nervous System Infections; Cerebral Ventriculitis; Encephalitis; Humans; Klebsiella Infections; Klebsiella pneumoniae; Male; Microbial Sensitivity Tests; Middle Aged; Tigecycline | 2022 |
Apramycin susceptibility of multidrug-resistant Gram-negative blood culture isolates in five countries in Southeast Asia.
Topics: Amikacin; Aminoglycosides; Anti-Bacterial Agents; Asia, Southeastern; Blood Culture; Carbapenems; Cephalosporins; Colistin; Drug Resistance, Multiple, Bacterial; Gentamicins; Gram-Negative Bacteria; Microbial Sensitivity Tests; Nebramycin; Pseudomonas aeruginosa; Tobramycin | 2022 |
Emergence of a Novel NDM-5-Producing Sequence Type 4523 Klebsiella pneumoniae Strain Causing Bloodstream Infection in China.
Topics: Aged; Amikacin; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamase Inhibitors; beta-Lactamases; Carbapenems; Cephalosporins; Colistin; Female; Formaldehyde; Humans; Klebsiella Infections; Klebsiella pneumoniae; Levofloxacin; Microbial Sensitivity Tests; Multilocus Sequence Typing; Phylogeny; Plasmids; Sepsis | 2022 |
IS
Topics: Amikacin; Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Humans; Klebsiella pneumoniae; Methyltransferases; Microbial Sensitivity Tests; Persistent Infection; Plasmids; RNA, Ribosomal, 16S; Tigecycline; Toxin-Antitoxin Systems | 2022 |
Whole genome sequencing of OXA-232-producing
Topics: Amikacin; beta-Lactamases; Carbapenem-Resistant Enterobacteriaceae; Carbapenems; Chromosomes; Ciprofloxacin; DNA Transposable Elements; Ertapenem; Humans; Klebsiella Infections; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests; Multilocus Sequence Typing; Phylogeny; Plasmids; Sepsis; Virulence; Virulence Factors; Whole Genome Sequencing | 2022 |
Emergence of NDM-1-producing
Topics: Amikacin; Anti-Bacterial Agents; Anti-Infective Agents; Bacterial Proteins; beta-Lactamases; Carbapenems; Clone Cells; Humans; Microbial Sensitivity Tests; Molecular Epidemiology; Pseudomonas aeruginosa; Pseudomonas Infections; RNA, Ribosomal, 16S | 2023 |
Molecular characterization of class 1 integrons in carbapenem-resistant Enterobacterales isolates.
Topics: Amikacin; Anti-Bacterial Agents; Carbapenems; Integrons; Microbial Sensitivity Tests; Trimethoprim, Sulfamethoxazole Drug Combination | 2023 |
The impact of multi-drug resistant Pseudomonas aeruginosa infections on acute pancreatitis patients.
Topics: Acute Disease; Amikacin; Anti-Bacterial Agents; Carbapenems; Case-Control Studies; Drug Resistance, Multiple, Bacterial; Gentamicins; Humans; Microbial Sensitivity Tests; Pancreatitis; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Tobramycin | 2023 |
Cefotaxime/sulbactam plus gentamicin as a potential carbapenem- and amikacin-sparing first-line combination for neonatal sepsis in high ESBL prevalence settings.
Topics: Amikacin; Ampicillin; Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Cefotaxime; Escherichia coli; Gentamicins; Humans; Infant, Newborn; Microbial Sensitivity Tests; Neonatal Sepsis; Prevalence; Sulbactam | 2023 |
Propranolol restores susceptibility of XDR Gram-negative pathogens to meropenem and Meropenem combination has been evaluated with either tigecycline or amikacin.
Topics: Amikacin; Carbapenems; Escherichia coli; Humans; Meropenem; Propranolol; Tigecycline | 2023 |
In vitro activity of ceftazidime-avibactam against Gram-negative strains in Chile 2015-2021.
Topics: Amikacin; Anti-Bacterial Agents; Carbapenems; Ceftazidime; Chile; Humans; Pseudomonas aeruginosa | 2023 |
Epidemiology and clinical characteristics of patients with carbapenem-resistant enterobacterales infections: experience from a large tertiary care center in a developing country.
Topics: Amikacin; Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Cross-Sectional Studies; Developing Countries; Escherichia coli; Female; Humans; Klebsiella pneumoniae; Male; Microbial Sensitivity Tests; Middle Aged; Pneumonia; Retrospective Studies; Sulfamethoxazole; Tertiary Care Centers; Trimethoprim | 2023 |